UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of sleep deprivation on the human metabolome

Proceedings of the National Academy of Sciences - PNAS, 2014-07, Vol.111 (29), p.10761-10766

2014

Volltextzugriff (PDF)

Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic

Cancer research (Chicago, Ill.), 2010-03, Vol.70 (6), p.2146-2157

2010

Volltextzugriff (PDF)

De novo phosphatidylcholine synthesis is required for autophagosome membrane formation and maintenance during autophagy

Autophagy, 2020-06, Vol.16 (6), p.1044-1060

2020

Volltextzugriff (PDF)

Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening

Journal of medicinal chemistry, 2016-10, Vol.59 (20), p.9337-9349

2016

Volltextzugriff (PDF)

Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

Clinical cancer research, 2013-11, Vol.19 (21), p.5940-5951

2013

Volltextzugriff (PDF)

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

Journal of medicinal chemistry, 2016-02, Vol.59 (3), p.1078-1101

2016

Volltextzugriff (PDF)

High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers

Molecular cancer therapeutics, 2019-10, Vol.18 (10), p.1696-1707

2019

Volltextzugriff (PDF)

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Molecular cancer therapeutics, 2009-07, Vol.8 (7), p.1725-1738

2009

Volltextzugriff (PDF)

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases

Cancer research (Chicago, Ill.), 2007-06, Vol.67 (12), p.5840-5850

2007

Volltextzugriff (PDF)

Presence of human breast cancer xenograft changes the diurnal profile of amino acids in mice

Scientific reports, 2022-01, Vol.12 (1), p.1008-1008, Article 1008

2022

Volltextzugriff (PDF)

p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance

Cancer research (Chicago, Ill.), 2016-05, Vol.76 (10), p.3025-3035

2016

Volltextzugriff (PDF)

Structure-Based Design of Orally Bioavailable 1H‑Pyrrolo[3,2‑c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)

Journal of medicinal chemistry, 2013-12, Vol.56 (24), p.10045-10065

2013

Volltextzugriff (PDF)

Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore

Bioorganic & medicinal chemistry letters, 2016-03, Vol.26 (5), p.1443-1451

2016

Volltextzugriff (PDF)

FGF7–FGFR2 autocrine signaling increases growth and chemoresistance of fusion‐positive rhabdomyosarcomas

Molecular oncology, 2022-03, Vol.16 (6), p.1272-1289

2022

Volltextzugriff (PDF)

Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity

Molecular cancer therapeutics, 2005-10, Vol.4 (10), p.1521-1532

2005

Volltextzugriff (PDF)

Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Molecular cancer therapeutics, 2016-06, Vol.15 (6), p.1412-1424

2016

Volltextzugriff (PDF)

The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery

Molecular cancer therapeutics, 2007-02, Vol.6 (2), p.428-440

2007

Volltextzugriff (PDF)

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

Molecular cancer therapeutics, 2011-02, Vol.10 (2), p.360-371

2011

Volltextzugriff (PDF)

Effect of acute total sleep deprivation on plasma melatonin, cortisol and metabolite rhythms in females

The European journal of neuroscience, 2020-01, Vol.51 (1), p.366-378

2020

Volltextzugriff (PDF)

Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing

Journal of medicinal chemistry, 2011-12, Vol.54 (24), p.8328-8342

2011

Volltextzugriff (PDF)

Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition

Proceedings of the National Academy of Sciences - PNAS, 2012-05, Vol.109 (20), p.E1267-E1276

2012

Volltextzugriff (PDF)

Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity

Molecular cancer therapeutics, 2007-12, Vol.6 (12), p.3147-3157

2007

Volltextzugriff (PDF)

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

Clinical cancer research, 2015-01, Vol.21 (1), p.77-86

2015

Volltextzugriff (PDF)

In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202

Clinical cancer research, 2005-07, Vol.11 (13), p.4875-4888

2005

Volltextzugriff (PDF)

Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors

Bioorganic & medicinal chemistry, 2011-11, Vol.19 (22), p.6949-6965

2011

Volltextzugriff (PDF)

1 – 25 von 301

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(283)
Mit Volltextzugriff
(283)

Publikationsform

Artikel
(300)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(191)
Life Sciences & Biomedicine
(172)
Humans
(157)
Animals
(89)
Mice
(79)
Female
(73)
Oncology
(69)
Pharmacology & Pharmacy
(57)
Cell Line, Tumor
(52)
Male
(46)
Chemistry, Medicinal
(44)
Biological And Medical Sciences
(43)
Medical Sciences
(42)
Pharmacology. Drug Treatments
(36)
Antineoplastic Agents - Pharmacology
(34)
Antineoplastic Agents
(33)
Life Sciences
(32)
Protein Kinase Inhibitors - Pharmacology
(30)
Tumors
(30)
Structure-Activity Relationship
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Effect of sleep deprivation on the human metabolome

Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic

De novo phosphatidylcholine synthesis is required for autophagosome membrane formation and maintenance during autophagy

Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening

Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases

Presence of human breast cancer xenograft changes the diurnal profile of amino acids in mice

p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance

Structure-Based Design of Orally Bioavailable 1H‑Pyrrolo[3,2‑c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)

Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore

FGF7–FGFR2 autocrine signaling increases growth and chemoresistance of fusion‐positive rhabdomyosarcomas

Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity

Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

Effect of acute total sleep deprivation on plasma melatonin, cortisol and metabolite rhythms in females

Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing

Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition

Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202

Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors

Suchergebnisse filtern